Europe Epigenetics Market - Segmented by Kits, Reagents, Enzymes, Instruments, Application, Technology, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4591850
  • Report
  • Region: Europe
  • 88 pages
  • Mordor Intelligence
until Dec 31st 2018
1 of 5


  • Diagenode Inc
  • Epitherapeutics
  • Illumina Inc
  • Merck & Co.
  • Qiagen
  • Roche
  • MORE
The Europe epigenetics market is estimated to register a high CAGR during the forecast period. Epigenetics is defined as the study of changes in gene expression, which is caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions.

Increasing Incidence and Prevalence of Cancer

According to WHO, more than 3.7 million of new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in Europe.

Europe comprises of only 1/8th of the total world population but it has around one quarter of the global total of cancer cases with 3.7 million new patients per year. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. As this epigenetics is used in the study of changes in gene expression, which are useful in the cancer diagnosis. So, with the increasing cancer prevalence the market is expected to grow. The other factors, like increasing funding for R&D in healthcare and the rising epigenetic applications in non-oncology diseases, are driving the epigenetics market.

Rising Cost of Instruments

The epigenetic instruments cost is rising gradually, and this increase is becoming one of the major restrains for the growth of the market. The instruments, such as mass spectrometers, sonicators, and the next generation sequences, are already costly, and the rising cost of these instruments are going to increase the cost for the genetic test, which simultaneously decreases the adoption rate of epigenetic instruments. Additionally, lack of skilled researchers is restraining the market growth of epigenetics.

The Germany has the Highest Market Share

In Europe, the Germany is dominating the epigenetics market due to the factors, such as increasing prevalence rate of cancer, increasing funding for the R&D, and the increasing collaborations between several large pharmaceutical companies for development of enhanced therapeutics.

Key Developments in the Market
  • December 2017 - Roche and Ignyta made definitive merger agreement (Roche to fully acquire Ignyta)
  • December 2017 - Zymo Research collaborated with Bertin

Reasons to Purchase the Report
  • Current and future market outlook for Europe epigenetics in the developed and emerging markets
  • Analyze various perspectives on the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth, during the forecast period
  • Identifying the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the market estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements.
Note: Product cover images may vary from those shown
2 of 5


  • Diagenode Inc
  • Epitherapeutics
  • Illumina Inc
  • Merck & Co.
  • Qiagen
  • Roche
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence and Prevalence of Cancer
6.1.2 Increasing Funding for R&D in Healthcare
6.1.3 Rising Epigenetic Applications in Non-Oncology Diseases
6.2 Market Restraints
6.2.1 Rising Cost of Instruments
6.2.2 Dearth of Skilled researchers
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Kits
7.1.1 Bisulfite Conversion Kits
7.1.2 Chip-seq Kits
7.1.3 RNA Sequencing Market
7.1.4 Whole Genome Amplification Market
7.1.5 5-HMC and 5-MC Analysis Kits
7.1.6 Other Kits
7.2 By Reagents
7.2.1 Antibodies
7.2.2 Buffers
7.2.3 Histones
7.2.4 Magnetic Beads
7.2.5 Primers
7.2.6 Other Reagents
7.3 By Enzymes
7.3.1 DNA - Modifying Enzymes
7.3.2 Protein Modifying Enzymes
7.3.3 RNA Modifying Enzymes
7.4 By Instruments
7.4.1 Mass Spectrometer
7.4.2 Sonicators
7.4.3 Next Generation Sequencers
7.4.4 Others
7.5 By Application
7.5.1 Oncology
7.5.2 Non-Oncology Inflammatory Diseases Metabolic Diseases Infectious Diseases Cardiovascular Diseases Others
7.5.3 Developmental Biology
7.5.4 Other Research Areas
7.6 By Technology
7.6.1 DNA Methylation
7.6.2 Histone Methylation
7.6.3 Histone Acetylation
7.6.4 Large noncoding RNA
7.6.5 MicroRNA modification
7.6.6 Chromatin Structures
7.7 By Geography
7.7.1 Europe France Germany United Kingdom Italy Spain Rest of Europe

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Diagenode Inc.
9.2 Epitherapeutics
9.3 Illumina, Inc.
9.4 Merck & Co.
9.5 Qiagen
9.6 Roche
9.7 Thermo Fisher Scientific
9.8 Zymo Research Corporation
*List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Diagenode Inc
  • Illumina Inc
  • Merck & Co.
  • Qiagen
  • Epitherapeutics
  • Thermo Fisher Scientific
  • Zymo Research Corporation
  • Roche
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown